

3D Organotypic Spinal Cultures: Exploring Neuron and Neuroglia Responses upon Prolonged Exposure to Graphene Oxide

Rossana Rauti¹, Mattia Musto¹, Neus Lozano², Elena Bonechi³, Clara Ballerini^{4*}, Kostas Kostarelos^{2*}, Laura Ballerini^{1*}

¹Scuola Internazionale Superiore di Studi Avanzati (SISSA), Italy, ²Nanomedicine Lab, Faculty of Biology, Medicine & Health and National Graphene Institute, AV Hill Building, University of Manchester, Manchester, United Kingdom, United Kingdom, ³Department NEUROFARBA, University of Florence, 50139 Florence, Italy, Italy, ⁴Laboratory of Neuroimmunology, Dipartimento di Medicina Sperimentale e Clinica, University of Firenze, Firenze, Italy, Italy

Submitted to Journal:
Frontiers in Systems Neuroscience

Article type:
Original Research Article

Manuscript ID:
429246

Received on:
05 Oct 2018

Revised on:
06 Dec 2018

Frontiers website link:
www.frontiersin.org

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Author contribution statement

M.M. and R.R. performed all cell biology, electrophysiology, and confocal experiments and analysis; N.L. and K.K. contributed to the synthesis and characterization of thin graphene oxide (s-GO); E.B. and C.B. designed and performed the supernatant measures; C.B. and L.B. conceived the study and the experimental design; C.B., R.R. and L.B. wrote the manuscript.

Keywords

Graphene, organotypic cultures, patch-clamp, Microglia, Microvesicles

Abstract

Word count: 245

Graphene-based nanomaterials are increasingly engineered as components of biosensors, interfaces or drug delivery platforms in neuro-repair strategies. In these developments, the mostly used derivative of graphene is graphene oxide. To tailor the safe development of graphene oxide nanosheets, we need to model in vitro tissue responses, and in particular the reactivity of microglia, a sub-population of neuroglia that acts as the first active immune response, when challenged by graphene oxide. Here, we investigated central nervous system tissue reactivity upon long-term exposure to graphene oxide nanosheets in 3D culture models. We used the mouse organotypic spinal cord cultures, ideally suited for studying long-term interference with cues delivered at controlled times and concentrations. In cultured spinal segments, the normal presence, distribution and maturation of anatomically distinct classes of neurons and resident neuroglial cells are preserved. Organotypic explants were developed for two weeks embedded in fibrin glue alone or presenting graphene oxide nanosheets at 10, 25 and 50 $\mu\text{g}/\text{mL}$. We addressed the impact of such treatments on premotor synaptic activity monitored by patch clamp recordings of ventral interneurons. We investigated by immunofluorescence and confocal microscopy the accompanying glial responses to graphene oxide exposure, focusing on resident microglia, tested in organotypic spinal slices and in isolated neuroglia cultures. Our results suggest that microglia reactivity to accumulation of graphene oxide flakes, maybe due to active phagocytosis, may trimm down synaptic activity, although in the absence of an effective activation of inflammatory response and in the absence of neuronal cell death.

Funding statement

We acknowledged financial support from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 696656 and No. 785219 Graphene Flagship

Ethics statements

(Authors are required to state the ethical considerations of their study in the manuscript, including for cases where the study was exempt from ethical approval procedures)

Does the study presented in the manuscript involve human or animal subjects: Yes

Please provide the complete ethics statement for your manuscript. Note that the statement will be directly added to the manuscript file for peer-review, and should include the following information:

- Full name of the ethics committee that approved the study
- Consent procedure used for human participants or for animal owners
- Any additional considerations of the study in cases where vulnerable populations were involved, for example minors, persons with disabilities or endangered animal species

As per the Frontiers authors guidelines, you are required to use the following format for statements involving human subjects: This study was carried out in accordance with the recommendations of [name of guidelines], [name of committee]. The protocol was approved by the [name of committee]. All subjects gave written informed consent in accordance with the Declaration of

Helsinki.

For statements involving animal subjects, please use:

This study was carried out in accordance with the recommendations of 'name of guidelines, name of committee'. The protocol was approved by the 'name of committee'.

If the study was exempt from one or more of the above requirements, please provide a statement with the reason for the exemption(s).

Ensure that your statement is phrased in a complete way, with clear and concise sentences.

All experiments were performed in accordance with the EU guidelines (2010/63/UE) and Italian law (decree 26/14) and were approved by the local authority veterinary service and by our institution (SISSA-ISAS) ethical committee. All efforts were made to minimize animal suffering and to reduce the number of animal used. Animal use was approved by the Italian Ministry of Health, in agreement with the EU Recommendation 2007/526/CE.

Data availability statement

Generated Statement: The datasets generated for this study are available on request to the corresponding author.

In review

3D Organotypic Spinal Cultures: Exploring Neuron and Neuroglia Responses upon Prolonged Exposure to Graphene Oxide

1 Mattia Musto^{1a}, Rossana Rauti^{1a}, Artur Filipe Rodrigues², Elena Bonechi³, Clara Ballerini^{4*}, Kostas
2 Kostarelos^{2*}, Laura Ballerini^{1*}

3 ¹ Neuron Physiology and Technology Lab, International School for Advanced Studies (SISSA),
4 Trieste, Italy

5 ² Nanomedicine Lab, Faculty of Biology, Medicine & Health and National Graphene Institute, AV
6 Hill Building, University of Manchester, Manchester, United Kingdom

7 ³ Department NEUROFARBA, University of Florence, 50139 Florence, Italy

8 ⁴ Laboratory of Neuroimmunology, Dipartimento di Medicina Sperimentale e Clinica, University of
9 Firenze, Firenze, Italy

10 ^a These authors equally contributed to the work

11 Correspondence:

12 E-mail: laura.ballerini@sissa.it, clara.ballerini@unifi.it and
13 kostas.kostarelos@manchester.ac.uk

14 **Keywords:** graphene oxide, organotypic cultures, patch-clamp, microglia, microvesicles

15 **Number of words:** 6809

16 **Number of figures:** 5 + 3 Supplementary

17 Abstract

18 Graphene-based nanomaterials are increasingly engineered as components of biosensors,
19 interfaces or drug delivery platforms in neuro-repair strategies. In these developments, the mostly
20 used derivative of graphene is graphene oxide. To tailor the safe development of graphene oxide
21 nanosheets, we need to model *in vitro* tissue responses, and in particular the reactivity of microglia, a
22 sub-population of neuroglia that acts as the first active immune response, when challenged by
23 graphene oxide. Here, we investigated central nervous system tissue reactivity upon long-term
24 exposure to graphene oxide nanosheets in 3D culture models. We used the mouse organotypic spinal
25 cord cultures, ideally suited for studying long-term interference with cues delivered at controlled
26 times and concentrations. In cultured spinal segments, the normal presence, distribution and
27 maturation of anatomically distinct classes of neurons and resident neuroglial cells are preserved.
28 Organotypic explants were developed for two weeks embedded in fibrin glue alone or presenting

29 graphene oxide nanosheets at 10, 25 and 50 $\mu\text{g}/\text{mL}$. We addressed the impact of such treatments on
30 premotor synaptic activity monitored by patch clamp recordings of ventral interneurons. We
31 investigated by immunofluorescence and confocal microscopy the accompanying glial responses to
32 graphene oxide exposure, focusing on resident microglia, tested in organotypic spinal slices and in
33 isolated neuroglia cultures. Our results suggest that microglia reactivity to accumulation of graphene
34 oxide flakes, maybe due to active phagocytosis, may trimm down synaptic activity, although in the
35 absence of an effective activation of inflammatory response and in the absence of neuronal cell death.
36

37 1. Introduction

38 Graphene is a monolayer sheet of carbon atoms, tightly bound in a hexagonal honeycomb
39 lattice. More specifically, graphene is an allotrope of carbon in the form of a two-dimensional film of
40 sp^2 hybridized carbon atoms (Kostarelos and Novoselov, 2014; Sanchez et al., 2012), characterized
41 by high mechanical strength and electrical conductivity, combined with optical transparency. In
42 neurobiology, graphene has been used in surface engineering of regenerative scaffolds to control the
43 neuro-induction of stem cells (Wang et al., 2012), and in that of neurological interfaces to improve
44 electrode performance (Kostarelos and Novoselov, 2014; Li et al., 2013; Mao et al., 2013; Wang et
45 al., 2011).

46 Graphene oxide (GO) is the most common derivative of graphene. Recently, GO materials
47 have been successfully designed for drug delivery applications (Liu et al. 2013; Yang et al., 2008,
48 2011; Baldrighi et al., 2016; Rauti et al., 2018). However, their potential persistence in biological
49 tissues requires investigating their safety. We have previously (Rauti et al., 2016) reported the ability
50 of small GO ($< 200 \text{ nm}$; s-GO) nanosheets to reduce synaptic activity at glutamatergic synapses
51 without affecting cultured hippocampal neurons survival. To date, only few studies addressed the
52 interaction between s-GO nanosheets and synapses (Bramini et al., 2016; Rauti et al., 2016), while
53 there are scarcely any data on the interactions between neural circuit function, s-GO tissue
54 accumulation and inflammation. Before any further exploitation of s-GO in synaptic targeting, a
55 detailed analysis of tissue responses to s-GO exposure is needed.

56 Mechanistic studies of the interplay between s-GO, the activation of microglia and synaptic
57 function, may require *in vitro* models to interrogate central nervous system (CNS) responses at
58 cellular resolution. Organotypic slices are explant cultures that preserve key, structural elements of
59 the tissue of origin (Avossa et al., 2003, 2006; Fischer et al., 1998; Furlan et al., 2007; Hailer et al.,
60 1996; Medelin et al., 2016; Schermer and Humpel, 2002; Tschertter et al., 2001) allowing detailed
61 studies of cellular and subcellular responses, such as inflammatory reactivity and synaptic efficacy
62 (Medelin et al., 2018), upon chronic treatments, including the exposure to exogenous factors. In the
63 CNS, the immune response is mediated by resident macrophages called microglia that are
64 approximately 12 % of the total CNS cells originating from myeloid cells. This subpopulation of
65 brain cells can switch between two different phenotypes: a ramified phenotype, typical of the resting
66 state, during which they “monitor” the surrounding environment (Cherry et al., 2014; Davalos et al.,
67 2005; Nimmerjahn et al., 2005) and an amoeboid phenotype, which is induced by antigen-mediated
68 stimulation. When activated, microglia rapidly changes its surface receptor expression and the

69 production of molecules involved in the immune response, like cytokines and chemokines (Fetler and
70 Amigorena, 2005; Nimmerjahn et al., 2005). Activated microglia may represent an active player in
71 neuron damage (Block et al., 2007).

72 We used mouse spinal organotypic cultures to mimic a chronic accumulation of s-GO in the
73 spinal cord tissue. The s-GO nanosheets were delivered to the spinal tissue upon dilution in the
74 chicken plasma (fibrin glue) used to embed the explants for culturing, thus allowing s-GO to rapidly
75 adsorb proteins (Bertrand et al., 2017), to mimic how nanosheets behave in a complex biological
76 milieu. We patch-clamped ventral interneurons to monitor synaptic transmission. Contextually, using
77 confocal microscopy we explored the effects of s-GO on innate immunity, in both organotypic slices
78 and primary isolated microglial cultures. We conclude that chronic accumulation of s-GO, due to
79 localisation of high doses of the material, significantly affected synaptic activity and the microglia
80 cell population. Our experiments in isolated microglial cells in culture support the direct response of
81 these cells to s-GO in these experimental conditions, however in organotypic cultures we did not
82 detect strong indicators of a switch toward the pro-inflammatory phenotype.
83

84 **2. Materials and Methods**

85 **2.1 Preparation of s-GO**

86 Synthesis and characterization of s-GO used in the present study were fully described in a separate
87 article (Rodrigues et al., 2018). Briefly, 0.8 g of graphite flakes (Graflake 9580, Nacional Grafite
88 Ltda., Brazil) were oxidized after mixing with 0.4 g of sodium nitrate (Merck-Sigma, UK) and 18.4
89 mL of sulfuric acid 99.999% (Merck-Sigma, UK), followed by 2.4 g of potassium permanganate
90 (Merck-Sigma, UK), according to the modified Hummers method, which was described in our
91 previous work (Ali-Boucetta et al., 2013; Rauti et al., 2016). After mixing for 30 min, 37.5 mL of
92 water for injections (Fresenius Kabi Ltd., UK) were added dropwise to ensure the safety of the
93 exothermic reaction taking place. The reaction temperature was further increased to 98 °C, and
94 maintained for another 30 min. The reaction was terminated after adding 112.5 mL of water for
95 injections, followed by the dropwise addition of 12.5 mL of hydrogen peroxide 30% (Merck-Sigma,
96 UK). The resulting mixture was purified by several rounds of centrifugation at 9000 rpm for 20 min,
97 until the supernatant reached a neutral pH and a viscous orange/brown layer of pure GO appeared on
98 top of the pelleted oxidation byproducts (Jasim et al., 2016; Rauti et al., 2016). GO was exfoliated
99 using warm water for injections and purified by centrifugation at 4000 rpm for 20 min to remove any
100 residual graphitic impurities. The obtained GO dispersion was aliquoted to depyrogenated glass vials,
101 which were exposed to a water bath sonicator (VWR, UK) operating at 80 W (45 kHz) for 5 min. The
102 sonicated dispersion was then centrifuged at 13000 rpm for 5 min, and the supernatant was collected
103 yielding s-GO nanosheets. All procedures were conducted under endotoxin-free conditions, which
104 were attained by setting the reaction under a laminar flow hood, using depyrogenated glassware and
105 nonpyrogenic plastic containers (Mukherjee et al., 2016).

106 Atomic force microscopy (AFM) images of s-GO were acquired using a Multimode 8 microscope
107 (Bruker, UK), operating in tapping mode using OTESPA tips (Bruker, UK). Twenty μL of s-GO,
108 diluted to a concentration of 100 $\mu\text{g/mL}$, were deposited on top of a freshly prepared mica surface

109 (Agar Scientific, UK) coated with poly-L-lysine (Sigma-Aldrich, UK), and dried overnight at 37 °C
110 prior to analysis. Full physicochemical characterization of s-GO is summarized in Figure S1.

111

112 **2.2 Preparation of spinal tissue slices and primary glial cultures**

113 Organotypic cultures were obtained from spinal cords isolated from E12 embryonic mouse (C57Bl),
114 as previously described (Avossa et al., 2003; Furlan et al., 2005, 2007; Usmani et al., 2016). Briefly,
115 pregnant mice were sacrificed by CO₂ overdose and decapitation and fetuses delivered by caesarean
116 section. Isolated fetuses were decapitated and their backs were isolated from low thoracic and high
117 lumbar regions and transversely sliced (275 µm) with a tissue chopper. Cultures were fixed on a glass
118 coverslip (Kindler, EU) with fibrin glue, i.e. reconstituted chicken plasma (Rockland) clotted with
119 thrombin (Merk). In graphene-treated cultures, s-GO (Rauti et al., 2016) nanosheets were embedded
120 in the fibrin glue at 10, 25 and 50 µg/mL final concentration. The distribution of s-GO within this
121 matrix was detected via confocal microscopy under reflection mode (see below; and Patskovsky et
122 al., 2015). Figure S2 shows the dispersion of s-GO at the different concentrations. Experiments were
123 performed on control and s-GO treated cultures after 2 and 3 weeks *in vitro*.

124 All experiments were performed in accordance with the UE guidelines (Directive 2010/63/UE) and
125 Italian law (decree 26/14) and were approved by the local authority veterinary service and by our
126 institution (SISSA-ISAS) ethical committee. All efforts were made to minimize animal suffering and
127 to reduce the number of animal used. Animal use was approved by the Italian Ministry of Health, in
128 agreement with the EU Recommendation 2007/526/CE.

129 Primary brain glial cultures were obtained from P2–P3 rats (Wistar) cortices, as previously described
130 (Calegari et al., 1999; Rauti et al., 2016). Dissociated cells were plated into plastic 75 cm² flasks,
131 incubated (37 °C; 5% CO₂) in culture medium consisting of DMEM (Invitrogen), supplemented with
132 10% FBS, 100 IU/ mL penicillin, and 10 mg/mL streptomycin.

133 Confluent mixed glial cultures from *days in vitro* (DIV) 21 to DIV 25 were treated with a trypsin
134 solution (0.25% trypsin, 1 mM EDTA in HBSS) diluted 1:4 in PBS for 30 minutes at 37 °C and 5%
135 CO₂. The medium was then collected and diluted 1:4 in DMEM supplemented with 10% FBS and
136 centrifuged for 5 minutes at 200 x g. The pellet was then re-suspended in DMEM supplemented with
137 10% FBS and mixed glial cultures conditioned medium (50:50) and plated on poly-L-lysine-coated
138 glass coverslips. Twenty-four hours after trypsinization half of the cultures were incubated with s-GO
139 at a concentration of 10 µg/mL suspended in the culture medium for 1 or 5 days.

140 All procedures were approved by the local veterinary authorities and performed in accordance with
141 the Italian law (decree 26/14) and the UE guidelines (2007/526/CE and 2010/63/UE). The animal use
142 was approved by the Italian Ministry of Health. All efforts were made to minimize suffering and to
143 reduce the number of animals used.

144

145 **2.3 Electrophysiological recordings**

146 For patch-clamp recordings (whole-cell, voltage clamp mode), a coverslip with the spinal culture was
147 positioned in a recording chamber, mounted on an inverted microscope (Eclipse TE-200, Nikon,
148 Japan) and superfused with control physiological saline solution containing (in mM): 152 NaCl, 4

149 KCl, 1 MgCl₂, 2 CaCl₂, 10 HEPES and 10 Glucose. The pH was adjusted to 7.4 with NaOH
150 (osmolarity 305 mosmol L⁻¹). Cells were patched with glass pipettes (4-7 MΩ) filled with a solution
151 of the following composition (in mM): 120 Kgluconate, 20 KCl, 10 HEPES, 10 EGTA, 2 MgCl₂ and
152 Na₂ATP. The pH was adjusted to 7.3 with KOH (295 mosmol L⁻¹). All electrophysiological
153 recordings were performed at room temperature (RT; 20-22 °C) and the spontaneous synaptic activity
154 was recorded by clamping the membrane voltage at -56 mV (not corrected for liquid junction
155 potential, which was -14 mV). Recordings were performed from ventrally located spinal
156 interneurons identified on the basis of previously reported criteria (Ballerini et al., 1999; Ballerini
157 and Galante, 1998; Galante et al., 2000). We detected no differences between controls (n = 45) and s-
158 GO (n = 39) neurons in cell membrane capacitance (70 ± 8 pF controls, 68 ± 6 pF s-GO) and
159 membrane input resistance (250 ± 28 MΩ controls, 242 ± 20 MΩ s-GO). Spontaneous activity was
160 also recorded in the presence of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 μM), bicuculline
161 (20 μM) and strychnine (10 μM) to pharmacologically discriminate between glutamatergic and
162 GABAergic PSCs, respectively. To detect miniature post-synaptic currents (mPSCs), TTX (1 μM;
163 Latoxan, Valence, France) was added. All reagents were purchased from Sigma-Aldrich, if not
164 otherwise indicated. Data were collected by Multiclamp 700B patch amplifier (Axon CNS,
165 Molecular Devices) and digitized at 10 kHz with the pClamp 10.2 software (Molecular Devices LLC,
166 USA). All recorded events were analyzed offline with the AxoGraph 1.4.4 (Axon Instrument) event
167 detection software (Axon CNS, Molecular Devices).

168

169 **2.4 Immunofluorescence labelling of spinal cord slices**

170 Organotypic cultures were fixed by 4% formaldehyde (prepared from fresh paraformaldehyde;
171 Sigma) in PBS for 1 hour at RT and then washed in PBS. Free aldehyde groups were quenched in 0.1
172 M glycine in PBS for 5 min. The samples were blocked and permeabilized in 3 % fetal bovine serum
173 (FBS), 3 % BSA and 0.3 % Triton-X 100 in PBS for 1 h at RT. Samples were incubated with primary
174 antibodies (mouse anti-neurofilament H Smi 32, Biolegend, 1:250 dilution; mouse monoclonal anti-
175 GFAP, Invitrogen, 1:500 dilution; rabbit monoclonal anti-caspase 3, Euroclone, 1: 200 dilution;
176 rabbit polyclonal anti-β-tubulin III, Sigma-Aldrich, 1:250 dilution; rabbit anti Iba1, Wako, 1:250
177 dilution) diluted in PBS with 5 % FBS at 4 °C, overnight. Samples were then incubated in secondary
178 antibodies (Alexa 488 goat anti-mouse, Invitrogen, 1:500 dilution; Alexa 594 goat anti-rabbit,
179 Invitrogen, 1:500 dilution), and DAPI (Invitrogen, dilution 1:200) to stain the nuclei, for 2 h at RT
180 and finally mounted on 1 mm glass coverslips using Vectashield hardset mounting medium (Vector
181 Laboratories). Images were acquired using a Nikon C2 Confocal, equipped with Ar/Kr, He/Ne and
182 UV lasers. Images were acquired with a 40× (1.4 NA) or 60× (1.5 NA) oil-objective (using oil
183 mounting medium, 1.515 refractive index). Confocal sections were acquired every 500 nm and the
184 total Z-stack thickness (50 μm) was set such that all emitted fluorescence was collected from the
185 sample. Regions of interest were confined to the ventral part of slice. Offline analysis was performed
186 using the open source image-processing package Fiji (Schindelin et al., 2012) and Volocity software
187 (Volocity 3D image analysis software, PerkinElmer, USA).

188

189 **2.5 Immunofluorescence labelling of neuroglia primary cultures**

190 Primary glial and microglial cultures were fixed by 4 % formaldehyde (prepared from fresh
191 paraformaldehyde) in PBS for 20 min at RT and then washed in PBS. Free aldehyde groups were
192 quenched in 0.1 M glycine in PBS for 5 min. The samples were blocked and permeabilized in 5 %
193 fetal bovine serum (FBS), 0.3 % Triton-X 100 in PBS for 30 min at RT. Samples were incubated
194 with primary antibodies (mouse monoclonal anti-GFAP, Invitrogen, 1:500 dilution; rabbit anti Iba1,
195 Wako, 1:250 dilution; mouse monoclonal anti-BrdU, Thermo Fisher, 1:200 dilution) diluted in PBS
196 with 5 % FBS at 4 °C, overnight. Samples were then incubated in secondary antibodies (Alexa 488
197 goat anti-mouse, Invitrogen, 1:500 dilution; Alexa 594 goat anti-rabbit, Invitrogen, 1:500 dilution),
198 and DAPI (Invitrogen, dilution 1:200) to stain the nuclei, for 45 minutes at RT and finally mounted
199 on 1 mm thick glass coverslips using Vectashield mounting medium (Vector Laboratories). Cells
200 densities were quantified at 20× (0.5 NA) magnification using a DM6000 Leica microscope (Leica
201 Microsystems GmbH, Wetzlar, Germany). In order to investigate the internalization of s-GO in
202 microglial cells, we used the reflection mode property during the confocal acquisition. Images were
203 acquired using a Nikon C2 Confocal, equipped with Ar/Kr, He/Ne and UV lasers. Images were
204 acquired with a 40× (1.4 NA) oil-objective (using oil mounting medium, 1.515 refractive index).
205 Confocal sections were acquired every 200 nm and the total Z-stack thickness 20µm.
206

207 **2.6 Bromodeoxyuridine (BrdU) incorporation**

208 Microglial primary cultures were incubated with BrdU (Thermo Fisher) diluted in the culture
209 medium at a final concentration of 10 µM for 24 hours. Cells were then washed with PBS and fixed
210 by 4 % formaldehyde (prepared from fresh paraformaldehyde) for 20 minutes at RT and then washed
211 with PBS (3 times, 2 minutes each). Free aldehyde groups were quenched in 0.1 M glycine in PBS
212 for 5 min. Cells were then incubated with HCl 1 M for 1 minutes on ice and with HCl 2 M for 15
213 minutes at 37 °C. Acid was then neutralized with boric acid 0.1 M for 10 minutes at RT. The samples
214 were then blocked and permeabilized in 3 % fetal bovine serum (FBS) and 0.3 % Triton-X 100 in
215 PBS for 1h at RT. Samples were incubated with primary antibodies at 4 °C overnight (mouse
216 monoclonal anti-BrdU, 1:200 dilution; rabbit anti-Iba1, 1:200 dilution). Samples were then incubated
217 in secondary antibodies (Alexa 488 goat anti-mouse, Invitrogen, 1:500 dilution; Alexa 594 goat anti-
218 rabbit, Invitrogen, 1:500 dilution), and DAPI (Invitrogen, dilution 1:200) to stain the nuclei, for 45
219 minutes at RT and mounted on 1 mm thick glass coverslips using Vectashield mounting medium
220 (Vector Laboratories).
221

222 **2.7 Microvesicle isolation**

223 Microvesicles shedding and detection by western blotting were performed as previously described
224 (Rauti et al., 2016). Microvesicles release was induced in 21 DIV microglial cells by the stimulation
225 with benzoyl-ATP (bzATP; 100 µM) in saline solution with the following composition: 125 mM
226 NaCl, 5 mM KCl, 1.2 mM MgSO₄, 1.2 mM KH₂PO₄, 2 mM CaCl₂, 6 mM D-glucose, and 25 mM
227 HEPES/NaOH (pH adjusted to 7.4), for 30 min at 37 °C and 5% CO₂. Microvesicles were then
228 pelleted by centrifugation (Bianco et al., 2009). Negative controls were incubated with saline solution
229 without the presence of bzATP. MVs were re-suspended in lysis buffer (50 mM Tris-HCl, pH 8.0,
230 150 mM NaCl, 1 % NP40, 0.1 % SDS), sonicated 3 × 10 s, and then boiled at 95 °C for 5 min.

231 Samples were run on a 10 % polyacrylamide gel and were blotted onto nitrocellulose filters
232 (Millipore, Italy). Filters were then blocked in PBS-Tween-20 (0.1 %) plus 5 % nonfat dry milk and
233 incubated with the primary antibody antiflotillin-1 (dilution 1:1000) for 16 h at 4 °C. Specific MV
234 marker flotillin-1 (Al-Nedawi et al., 2008; del Conde et al., 2005) was detected with mouse
235 monoclonal antiflotillin-1 (dilution 1:1000). After three washes with PBS-Tween, filters were
236 incubated with peroxidase-conjugated anti-mouse secondary antibody (dilution 1:1000). Optical
237 density of immunolabeled ECL-exposed protein bands was measured with UVI-1D software.
238

239 **2.8 Microglial morphological analysis**

240 For morphological analysis cells were fixed and immunostained for Iba1 and DAPI for nuclei, as
241 described above and images were acquired with a 40 × oil objective. The quantitative analysis of cell
242 morphology was performed with the particle analysis feature in Fiji (1.51v) to automatically measure
243 the area, perimeter and Feret's maximum diameter. In particular, Feret's diameter is described as the
244 greatest distance between any two points along cell perimeter and is considered as an index of cell
245 length (Caldeira et al., 2014; Kurpius et al., 2006; Mitchell et al., 2018; Torres-Platas et al., 2014;
246 Zanier et al., 2015). A more ramified cell has a higher value for this parameter, while a more
247 amoeboid shape is described by a lower value. We also evaluated the transformation index (Caldeira
248 et al., 2014; Fujita et al., 1996) which is calculated as $[\text{perimeter of cell } (\mu\text{m})]^2/4\pi [\text{cell area } (\mu\text{m}^2)]$
249 and describes the degree of cellular ramification. Cells with long processes and small cell body
250 display larger values of the transformation index, which depends on the cell shape regardless the cell
251 size.
252

253 **2.9 Measurement of cytokines and chemokines**

254 In a small set of experiments an inflammatory response was induced (Hanisch, 2002), by incubating
255 organotypic slices, for 6 hours, with a cocktail of the following mouse recombinant cytokines: TNF- α
256 (R&D Systems, #210-TA/CF), IL-1 β (R&D Systems, #M15330), GM-CSF (R&D Systems,
257 #P04141), 10 ng/mL each, or with lipopolysaccharide (LPS, 1 ng/mL). Inflammatory reaction may be
258 detected by cytokine and chemokine production. A panel of 12 out of cytokines or chemokines was
259 measured in organotypic culture supernatants after 2 weeks culturing, by Luminex based technology,
260 using a customized Procarta plex Immunoassay kit (Invitrogen), following the manufacturer's
261 protocol. The following soluble factors were simultaneously measured in 50 μl of supernatant: IL4,
262 IL6, IL10, IL17, IL21, BAFF, IFN γ , TNF α , CXCL1, CXCL2, CXCL10, MCP1.
263

264 **2.10 Statistical Analysis**

265 The results are presented as the mean \pm SD, if not otherwise indicated. Statistically significant
266 difference between two data sets was assessed by t-statistic, in particular by Student's *t*-test (after
267 checking variances homogeneity by Leven's test) for parametric data and by Mann-Whitney's test for
268 non-parametric ones (Statistica 6.0 – StatSoft Italy). Differences among multiple groups were
269 evaluated by F-statistic with two-way ANOVA, followed by the Holm-Sidak test for multiple
270 comparison (Sigmaplot 12.0 – Systat Software).

271 A statistically significant difference between two data sets was assessed and $P < 0.05$ was considered
 272 statistically significant.

273 In box-plots, the thick horizontal bar indicates the median value, the cross indicates the mean value,
 274 the boxed area extends from the 25th to 75th percentiles while whiskers from the 5th to the 95th
 275 percentiles.

276

277 **3. Results**

278 **3.1 Long-Term Exposure to High Doses of s-GO Impaired Network Activity in Spinal-Cord**

279 **Organotypic Slices.** We first explored the long-term (2 weeks) exposure of neural tissue to s-GO in
 280 3D tissue cultures. s-GO was delivered to the neural tissue *via* the fibrin glue, the thick matrix
 281 obtained by chicken plasma and thrombin in which slices are embedded (see Methods), that
 282 represents the explant growth environment. Figure 1A shows a reconstruction at low confocal
 283 magnification of a spinal cord slice after 14 days of growth, labelled for neurofilament H (Smi-32; in
 284 green) and for the nuclei (DAPI, in blue). The entire area of tissue growth is visualized, and it
 285 includes the spinal slice, at the centre, and the outgrowing area comprising the co-cultured dorsal root
 286 ganglia (DRG) and the typical, dense mesh of Smi-32⁺ neurites in the surrounding outgrowth belt
 287 (Fabbro et al., 2012).

288 Spinal organotypic slices upon 2 weeks of culturing exhibit an intense spontaneous synaptic
 289 activity (Ballerini and Galante, 1998; Furlan et al., 2007; Streit, 1993). We patch clamped (sketched
 290 in Figure 1B) visually identified ventral interneurons (at holding potential, V_h of -56 mV) in control
 291 cultures ($n = 45$) and in s-GO treated ones ($n = 52$), and we recorded spontaneous, basal postsynaptic
 292 currents (PSCs). Figure 1C shows representative tracings in control (top) and after exposure to the
 293 highest dose (50 $\mu\text{g/mL}$) of s-GO (bottom). In all culture groups, PSCs appeared as heterogeneous
 294 inward currents of variable amplitudes, characterized by different kinetic properties (fast decaying
 295 events, with decay time constant (τ) of 6 ± 2 ms and slow decaying events with $\tau 22 \pm 6$, $n = 15$, see
 296 sample in Figure 1C, right panel; Medelin et al., 2018).

297 The chronic (2 weeks) exposure to low (10 $\mu\text{g/mL}$) doses of s-GO did not affect PSCs
 298 amplitude and frequency values (39 ± 7 pA and 23 ± 5 Hz, $n = 13$) when compared to control ones
 299 (42 ± 6 pA and 24 ± 4 Hz, $n = 15$; plots in Figure 1D). Conversely, higher s-GO doses significantly
 300 (25 and 50 $\mu\text{g/mL}$, $P < 0.05$ and $P < 0.01$, respectively; two-way ANOVA) reduced PSCs frequency
 301 (from 24 ± 6 Hz in control to 14 ± 3 Hz, in s-GO 25 $\mu\text{g/mL}$, $n = 15$ and 13; from control 22 ± 8 Hz to
 302 10 ± 2 Hz in s-GO 50 $\mu\text{g/mL}$, $n = 15$ and 13; plot in Figure 1D, left). Upon s-GO treatments, PSCs
 303 decay kinetics (fast decaying, $\tau 5 \pm 2$ ms and slow decaying $\tau 26 \pm 3$, $n = 13$ at 50 $\mu\text{g/mL}$, see sample
 304 Figure 1C bottom row, right) and amplitudes were not altered by these treatments (Figure 1D, right).
 305 In 25 and 50 $\mu\text{g/mL}$ s-GO treated cultures we investigated the amount of neuronal apoptosis in
 306 respect to aged-matched controls by measuring the expression of active caspase-3 (Cohen, 1997).
 307 Active caspase-3 positive cells were quantified in the ventral spinal horns (Figure 1E, in red). We
 308 detected a comparative amount of apoptotic cells in all conditions (in control: 15 ± 3 Caspase-3
 309 positive cells/ mm^2 namely 3.7 % of the total amount of cells, $n = 10$ visual fields and in s-GO 50
 310 $\mu\text{g/mL}$; 20 ± 3 Caspase-3 positive cells/ mm^2 , 4.3 % of the cells, $n = 10$ visual fields; plot in Figure
 311 1E). Thus, s-GO only when delivered at higher concentrations altered synapse function, without
 312 increasing neuronal cell death.

313 Miniature synaptic currents (mPSCs; Figure 2) were recorded in a subset of control (n = 12)
 314 and s-GO treated (n = 13) neurons by application of tetrodotoxin (TTX, 1 μ M), to block voltage-
 315 gated sodium channels. As this treatment impairs the generation of action potentials, mPSCs reflect
 316 the stochastic release of vesicles from the presynaptic terminals at individual synapses impinging
 317 onto the recorded neuron. Their frequency depends on the pre-synaptic release probability and on the
 318 number of synaptic contacts, while their amplitude depends on postsynaptic receptor sensitivity
 319 (Raastad et al., 1992). In neurons exposed to low (10 μ g/mL) s-GO, mPSCs frequency was not
 320 affected (from 19 ± 3 Hz in control to 15 ± 3 Hz in s-GO treated slices; plot in Figure 2). When
 321 investigating the impact of higher graphene doses (25 and 50 μ g/mL), we detected a significant
 322 difference ($P < 0.05$ and $P < 0.01$, respectively; two-way ANOVA) in mPSCs frequency (from 20 ± 3
 323 Hz to 13 ± 2 Hz in s-GO 25 μ g/mL and from 16 ± 3 Hz to 6 ± 1 Hz in s-GO 50 μ g/mL). s-GO did not
 324 affect the amplitude of the recorded events (from 27 ± 6 pA in controls to 32 ± 5 pA in s-GO 10
 325 μ g/mL; from 29 ± 5 pA in controls to 27 ± 4 pA in s-GO 25 μ g/mL; from 33 ± 8 pA in controls to 30
 326 ± 6 pA in s-GO 50 μ g/mL).

327 In s-GO neurons (50 μ g/mL) we pharmacologically (see Methods) isolated AMPA-receptor
 328 mediated glutamatergic mEPSCs (n = 13) or GABA_A- receptor mediated mIPSCs (n = 13), both
 329 detected as inward currents in our recording conditions (Medelin et al., 2016). mEPSCs and mIPSCs
 330 frequency values were similarly reduced by s-GO when compared to control slices (for mEPSPs in
 331 controls 14 ± 4 Hz, n = 12; in s-GO 7 ± 2 Hz, n = 13; $P < 0.05$, Student's *t* test; histograms in Figure
 332 2, bottom-left panel; for mIPSCs in controls 13 ± 4 Hz, n = 12; in s-GO 5 ± 2 Hz, n = 13; $P < 0.05$,
 333 Student's *t* test; histograms in Figure 2, bottom-right panel).

334
 335 **3.2 s-GO Exposure at High Doses Induced Microglial Proliferation.** To investigate tissue
 336 reactivity accompanying s-GO ability to alter synaptic signalling, we used the highest dose tested,
 337 namely the s-GO at 50 μ g/mL. In organotypic slice cultures, neuroglia resident cells are mainly
 338 represented by astrocytes (GFAP positive cells) and microglia (Iba1 positive cells; Medelin et al.,
 339 2018).

340 GFAP-positive astrocytes are not immune cells *per se*, but can, under certain conditions,
 341 contribute to the immune response (Farina et al., 2007). In organotypic cultures upon 2 weeks of
 342 culturing, these cells are usually characterized by a stellate-like morphology (Figure 3A; Avossa et
 343 al., 2003) and their density was not significantly altered by s-GO treatment (Figure 3A, right
 344 histograms; 500 ± 70 GFAP-positive cells/mm² in control and 650 ± 90 GFAP-positive cells in s-
 345 GO; n = 13 visual fields each). Iba1-positive microglia cells are known mediators of CNS
 346 inflammation. In contrast to astrocytes, the density of Iba1-positive cells was significantly ($P <$
 347 0.01 , Student's *t* test) increased in slices exposed to s-GO (47 ± 17 Iba1-positive cells/mm², n = 10
 348 fields in control and 150 ± 30 Iba1-positive cells/mm², n = 11 fields for s-GO; Figure 3B).

349 To further investigate glia cell reactivity to s-GO treatment in complex systems, we measured
 350 from the spinal cord cultures supernatant (n = 6 slices for each conditions) the presence of cytokine
 351 and chemokine after 2 weeks of continuous exposure. In s-GO we detected an increased trend of
 352 expression, when compared to controls, of CXCL2, and MCP1, T lymphocytes and monocytes recall
 353 factors, and IL6, IL10, BAFF and TNF α , cytokines responsible for pro-inflammatory responses (IL6,
 354 TNF α), regulatory function (IL10) and homeostatic B cell survival (BAFF), however the profiles of

soluble factors production obtained from our analysis, did not reach statistical significance (Figure 3C). These observations are in line with a limited or even absent sustained activation of microglial cells toward both polarized forms: M1 and M2, or most probably toward an intermediate one (Kabba et al., 2018).

359

3.3 s-GO Exposure Induces Microglial Proliferation in Neuroglial Cultures. The increased density of microglial cell in the absence of significant increased production and release of chemokines and cytokines after 2 weeks exposure to high s-GO dose, prompted us to directly investigate the effects of s-GO on microglial cell types in isolated glial preparations, obtained from early post-natal rats (P2-P3). Due to the relatively low-cell density typical of cultures comprising isolated Iba1-positive cells, as shown in Figure 4A (control), we exposed the cells for 5 days to a lower (10 $\mu\text{g}/\text{mL}$) dose of s-GO. s-GO readily increased Iba1-positive cell-density, as shown in Figure 4A, a response reminiscent of the one observed in organotypic slices (Figure 3B). In order to assess whether s-GO sheets induced microglia reactivity, we analysed the cellular shape, a traditionally accepted index of the phenotypes microglia acquires when entrained in tissue responses. In particular, a highly ramified shape is linked to a surveillant state in which microglia actively monitors the surrounding environment. On the other hand, an amoeboid phenotype may indicate the transition to the activated, pro-inflammatory state (Saijo and Glass, 2011). Consistent with a transformation from a ramified to an amoeboid phenotype, the perimeter, Feret's maximum diameter and transformation index (plot in Figure 4B), significantly decreased ($P_{\text{perimeter}} < 0.0001$, $P_{\text{Feret's diameter}} = 0.0035$, $P_{\text{transformation index}} < 0.0001$; Mann-Whitney test) after 6 days of s-GO exposure, compared to control ($n = 10$ visual fields for both conditions; 3 different cultures series). The measured parameters reliably describe morphological changes and cell length. In particular, the Feret's maximum diameter is defined as the highest distance between any two points along the cell perimeter while transformation index describes cellular ramification.

Next, we analysed the number of cycling cells present in each culture group (control and s-GO). For this purpose, cells were pulsed at 24 h and at 5 days with 10 mM bromodeoxyuridine (BrdU) prior to fixation. The number of cells that had incorporated the nucleotide analogue was then assessed by immunofluorescence, using anti-BrdU-specific antibodies. In Figure 4C the box plot shows the $\text{BrdU}^+/\text{Iba1}^+$ ratio, an index of microglial cells that incorporated BrdU in the newly synthesized DNA during cell division, providing a quantitative measure of proliferative capacity of cells (Nowakowski et al., 1989). The higher $\text{BrdU}^+/\text{Iba1}^+$ ratio was already significant at 24 hours of s-GO exposure ($\text{median}_{\text{GO}} = 0.85$; $\text{median}_{\text{control}} = 0.08$), suggesting an early interaction of microglia with small graphene sheets. The increased proliferation was more pronounced after five days of incubation with s-GO ($\text{median}_{\text{GO}} = 0.2$; $\text{median}_{\text{control}} = 0.45$; $P < 0.001$, Mann-Whitney test, for both time points; $n=10$ fields for each condition; 4 different cultures).

Microvesicles (MVs), released from almost all cell brain types, are, in general, an emerging intercellular communication over long-range distance. In particular, MVs discharged by microglial cells represent a secretory pathway for inflammatory cytokine (Turola et al., 2012) potentially promoting propagation of neuroinflammatory responses in the brain. We measured the release of MVs from isolated microglial cultures in control or exposed to s-GO by western blot analysis for the protein flotillin-1, a marker of lipid rafts that are specific plasma membrane regions were the

397 probability of MVs release is higher (Figure 4D; Rauti et al., 2016). Pharmacological stimulation by
398 bzATP induces only a slight release of MVs in isolated microglial cells, as depicted by the
399 particularly weak signal in the specific band (Figure 4D). Interestingly, bzATP stimulation in the
400 presence of s-GO triggers a massive microglia shedding of MVs, shown by the high intensity of the
401 band (Figure 4D).

402
403 **3.4 Localization of s-GO in microglial cells.** We then directly investigated the fate of s-GO in
404 isolated microglia cultures using confocal microscopy reconstructions. Iba1-positive cells (2 different
405 culture series) were exposed for 3 days to s-GO (10 $\mu\text{g}/\text{mL}$). We tested the presence of s-GO sheets
406 within Iba1 positive cells by operating the confocal microscopy under reflection mode, which allows
407 the visualization of s-GO (Jung et al., 2007; Kim et al., 2010; Bramini et al., 2016; Chiacchiaretta et
408 al., 2018). Figure 5A shows confocal reconstructions of control and treated Iba1 positive cells. In s-
409 GO-treated cells, GO nano-sheet aggregates (in yellow, reflection mode) were detected inside
410 microglial cells (in grey, Iba1⁺) by z-stack reconstruction (Figure 5, top panels: 40 \times ; 100 \times 100 μm^2
411 visualized area). In Figure 5, high magnification confocal micrographs (control and s-GO treated,
412 bottom panels) are shown (60 \times ; 50 \times 50 μm^2 visualized area) depicting a single microglia (grey) cell
413 co-localisation with the reflected signal of graphene (yellow). The orthogonal view of the z-
414 projection shows the XZ and YZ planes (bottom side and right side of the z-stack reconstructed
415 image, respectively) of the acquired fields. As expected from cells that act as macrophages, the
416 material were internalized and stocked inside the cell, forming small aggregates, appreciable by the
417 orthogonal reconstruction. The signal of s-GO was not present in control cells, either in the z-stack
418 reconstruction or in the orthogonal planes (Figure 5, left panels).

419

420

421 **4. Discussion**

422

423 We used here organotypic spinal cord cultures to test tissue responses to s-GO prolonged
424 exposure. In particular, we were interested in assessing microglia reactivity in cultured neural
425 explants, where immune resident cells are present, but not supported by the peripheral ones.
426 Organotypic spinal slices represent a biological model of segmental spinal microcircuit useful for
427 studying the dynamics of intrasegmental processes. A long series of studies has indicated that the
428 organotypic cultures from mouse spinal cord represent a valuable *in vitro* model system to study the
429 mechanisms of development, neurogenesis, glial differentiation, myelination, muscle formation, and
430 synaptogenesis leading to early post natal features, upon 2 weeks of culturing (Avossa et al., 2003;
431 Rosato-Siri et al., 2004; Fabbro et al., 2007; Sibilla et al., 2009; Furlan et al., 2007; Medelin et al.,
432 2016). More recently, we confirmed the presence of heterogeneous neuroglial cells after 2 weeks of
433 *in vitro* growth and we further documented in organotypic spinal tissue the induction, by short-term
434 incubation with pro-inflammotry CKs cocktail, of a reliable release of cytokines and chemokines,
435 mostly due to the local generation and delivery of inflammatory factors (Medelin et al., 2018). Thus,
436 our experimental model is ideally suited to dissect spinal resident cells ability in modulating local
437 inflammatory tissue reactivity.

438 The major result of the present investigation is that the long-term accumulation of s-GO
439 (when delivered at high doses) affected resident microglia and, in the absence of an effective
440 clearance, may induce a subtle, although chronic, reactive state, potentially trimming down synaptic
441 activity, as physiologically occurring during development (Paolicelli et al., 2011). In fact, in our
442 experiments, both GABAR- and AMPAR-mediated mPSCs were reduced in frequency upon s-GO
443 exposure at high concentrations. The reduction in miniatures' frequency, but not in their amplitude,
444 strongly suggests a reduction in the number of synapses or of release sites (Rauti et al., 2016). This
445 down-regulation of synapses is apparently not due to a general cell membrane disruption or to
446 neuronal apoptosis. In fact, we never detected alterations in basic electrophysiological parameters,
447 reflecting neuronal health and membrane integrity (Carp, 1992; Djuric et al., 2015). This indicated,
448 together with the absence of up-regulated apoptosis that the synaptic events diminished not as a
449 consequence of direct neuronal damage brought about by s-GO.

450 In organotypic slices, both glutamate- and GABA-mediated synapses were down-regulated by
451 s-GO, this result differs from our previous report, where s-GO down-regulated selectively
452 glutamatergic release sites in hippocampal cultures (Rauti et al., 2016). Considering the similarity of
453 the s-GO batch used here compared to our previous study (Figure S1), the lack of specific synaptic
454 targeting may be related to several factors, such as the diverse CNS regions tested, i.e. ventral spinal
455 cord vs hippocampus, the initially more immature stage of network and synapse development
456 (embryonic vs postnatal) or the s-GO higher concentrations. In this context, it is relevant to note the
457 s-GO delivery modality used here: s-GO was accumulated in the fibrin glue embedding the spinal
458 culture and, presumably, was from here released along 2 weeks of culturing. Thus the potential
459 formation of a protein corona might have affected the nanoparticle biological fate (Hadjidemetriou et
460 al., 2015) favouring active phagocytosis by neuroglia and preventing the direct synapse interference
461 described in our previous report (Rauti et al., 2016). It is tempting to speculate that the presence in
462 the spinal explants of resident neuroglia resulted in active phagocytosis restricted to intrinsic
463 microglia, without the involvement of blood cells such as macrophages. Such an activation could
464 have induced a generic microglia response, known as synaptic stripping, ultimately leading to
465 indiscriminate synapse reduction (Kettenmann et al., 2013).

466 In spinal organotypic slices exposed to s-GO, the presence of tissue reactivity is indicated
467 only by the observed increase in microglia cell-density, in the absence of increased GFAP+
468 astrocytes, suggesting only a mild state of reactivity (Liddelw et al., 2017; Okada et al., 2018;
469 Olson, 2010). Interestingly, the cytokines and chemokines profiles measured in organotypic cultures
470 supernatant, although slightly altered, were not significantly increased after 2 weeks of s-GO
471 exposure. In this regard, we did not find an increase in IL-6, that is produced by astrocyte
472 following, for example, a proinflammatory stimulation (Ulivieri et al., 2016). Therefore, in this
473 model, we may hypothesize that microglial proliferative response with no significant variation in
474 cytokines production after 2 weeks, does not involve a shift into the M1 phenotype.

475 The results in this study obtained with isolated Iba1⁺ cells are in support of a direct activation
476 of microglial cells as a consequence of active s-GO phagocytosis. s-GO boosted microglia
477 proliferation leading to a significantly higher cell density in pure neuroglia cultures, accompanied by
478 the typical morphological switch from a ramified to an amoeboid phenotype (Cherry et al., 2014;
479 Kettenmann et al., 2011; Nimmerjahn et al., 2005; Saijo and Glass, 2011), suggestive of an active

480 role of Iba1-positive cells in the tissue reaction to graphene, even in the virtual absence of other cell
481 types. The direct activation of microglia was apparently related to fast internalization of s-GO flake
482 aggregates that occurs during the first 24h after the exposure.

483 We thus suggest that s-GO, accumulated via the fibrin glue, activates resident microglia
484 phagocytosis. This hypothesis is also supported by the observation that pure microglial cultures
485 grown and exposed to s-GO in a serum-free medium did not show a proliferation boost comparable
486 to that found in the presence of FBS (Figure S3). As already discussed above, the interaction of
487 nanoparticles such as s-GO with biological fluids may affect their fate and effectiveness. In fact, the
488 corona formation takes place not only in the presence of plasma proteins like fibrinogen but also with
489 proteins present in the serum (Gräfe et al., 2016). Therefore, the proliferative response found in both
490 pure microglial cultures and organotypic slices exposed to s-GO, despite their different origin and
491 architecture, may be explained by an increase of the efficacy in the uptake of the material (Walkey et
492 al., 2012) by microglia and mediated by s-GO interactions with the proteins pool of plasma and
493 serum.

494 An additional indication of microglia reactivity in s-GO was provided by the increased release
495 of shed vesicles induced by bzATP. MVs released by microglia have been reported to affect synaptic
496 activity, mainly acting at the presynaptic site of the excitatory synapses, but increasing synaptic
497 activity and glutamate release in primary cultures (Antonucci et al., 2012) thus it seems unfeasible
498 that the down-regulation in synaptic activity detected in this study be mediated by MVs release.

499 One possibility is that, in the current experimental conditions, the global reduction in synaptic
500 activity is mostly due to the emergence of chronic, although mild, tissue reactivity. Such reactivity
501 follows microglia phagocytic activity of protein-decorated s-GO flakes. Ultimately, we have to ask
502 ourselves whether these data indicate a potential *in vivo* inflammatory response due to s-GO sheets.
503 There are several relevant aspects that limit reporting it as an inflammatory response. First of all, the
504 conditions we tested involved the delivering of s-GO to a “closed” biological system, allowing only
505 resident macrophages to interact with it and limiting the contribution of neighbour tissues in the
506 interaction with this material, as it would happen in an *in vivo* model. The lack of significance in the
507 chemokine and cytokine increase in concentration suggests a mild immune response that may not
508 necessarily lead to a pathological inflammatory state or alternatively indicates a return to a
509 physiological condition, from an intermediate immune activation. Last, astrocytes, which depend on
510 microglia activation to be polarized to pro-inflammatory cells did not show, in this context, reactive
511 gliosis. To note, a recent report (Song et al., 2014) investigated microglia pro- and/or anti-
512 inflammatory responses when challenged by different graphene structures, and documented anti-
513 inflammatory effects of 3D-graphene foams.

514
515 Microglia produces immune mediators secondary to neuronal stimulation, (i.e. tissue injury),
516 or following a direct stimulus to microglia itself. Here we report an increased proliferation rate of
517 Iba1-positive cells, suggestive of microglia activation, and consistent with morphological
518 observations. However, the detected cell activation seems to involve a group of cells, not all of them,
519 and this may explain the fact that we observed only a trend toward increased production of immune
520 factors, without significant variations. We may hypothesize that the fraction of activated microglia
521 includes cells in direct contact to s-GO. Indeed, microglia is often reported to function similarly to

522 other myeloid cells, the macrophages, able to scavenge the environment, perform phagocytosis,
523 antigen presentation and to react to contact with nano materials (Aldinucci et al., 2013; Jin and
524 Yamashita, 2016) in order to maintain CNS homeostasis, with both detrimental and beneficial
525 effects. It is important to underline that eventually the pro-inflammatory molecules, present before
526 and after s-GO contact, were not inducing astrogliosis. Therefore, as a side effect, our in vitro model
527 allows the direct observation and study of material/neuron interactions in the presence of glial cells,
528 and also simulates accumulation of material in CNS providing useful insights on the potential
529 consequences.

530 The function of microglia, brain macrophages, is still poorly understood. In mice there are
531 at least two subtypes: inflammatory and non-classical patrolling cells (Nimmerjahn et al., 2005),
532 and also a CNS region-dependent microglial heterogeneity has been suggested, suggesting that
533 microglia, although in many different ways, is constantly activated. In this complex picture, we
534 were interested in investigating whether s-GO induced an inflammatory reaction. Our results
535 indicate that this was not the case. Further studies should indeed address the interplay between
536 microglia and s-GO, for example by single cell RNA sequencing (Matcovitch-Natan et al., 2016),
537 a method that has sufficient sensibility to determine the functional/phenotypic response of these
538 important brain-macrophage cell population.

539
540

In review

541 **5. Figures**

542 **Figure 1. s-GO reduced basal synaptic activity in a dose-response fashion without inducing cell**
 543 **death in organotypic ventral horns.** In (A), low magnification confocal micrograph of a spinal cord
 544 slice culture (14 DIV) immune-labelled for neurofilament H (SMI-32; in green) and nuclei (DAPI; in
 545 blue). Scale bar 500 μm . The arrow head indicates the ventral fissure, localizing the ventral horns,
 546 while the arrows the co-cultured DRGs. In (B), sketch of the experimental setting for ventral
 547 interneuron single cell recordings (modified with permission from Usmani et al., 2016). In (C),
 548 tracings represent spontaneous synaptic activity recorded from ventral interneurons in Control (top)
 549 and s-GO treated slices (bottom; 50 $\mu\text{g}/\text{mL}$). On the right panel, isolated fast and slow PSCs are
 550 shown superimposed (electronic average trace superimposed in white) for the control (top) and s-GO
 551 treated (bottom) recordings (same cells as above). In (D), the plots summarize the average PSCs
 552 frequency (left) and amplitude (right) values; note the reduction in PSC frequency upon s-GO
 553 treatments (25 and 50 $\mu\text{g}/\text{mL}$) (* $P < 0.05$ and ** $P < 0.01$). In (E), confocal micrographs visualize
 554 caspase-3 positive cells (in red) in the ventral horns, counter-stained for β -tubulin III (in green, to
 555 visualize neurons) in Control (left) and s-GO (50 $\mu\text{g}/\text{mL}$; right) treated slices. Nuclei are visualized
 556 by DAPI (blue). Scale bar: 50 μm . The column plot summarizes the density of caspase and β -tubulin
 557 double positive cells; note the absence of statistical significant differences between the two
 558 conditions.

559
 560 **Figure 2. Miniature synaptic currents are down regulated by s-GO in organotypic ventral**
 561 **horns.** Sample tracings are mPSCs recorded in Control and s-GO (50 $\mu\text{g}/\text{mL}$) treated cultures (top
 562 left panel). Top right: plot reporting mPSCs frequency values in control and in the three different s-
 563 GO concentrations tested. Note that s-GO treatments (25 and 50 $\mu\text{g}/\text{mL}$) significantly decreased the
 564 frequency of mPSCs (* $P < 0.05$ and ** $P < 0.01$). Bottom: column plots summarize the average
 565 values of AMPA-glutamate (left; mEPSCs) and GABA_A (right, mIPSCs) receptor mediated
 566 miniature events, pharmacologically isolated. In s-GO treatments (50 $\mu\text{g}/\text{mL}$) a significant decrease
 567 in the frequency of both types of miniature was detected (* $P < 0.05$ and ** $P < 0.01$, respectively).

568
 569 **Figure 3. Tissue reactivity in organotypic spinal cultures exposed to s-GO at high dose.** In (A),
 570 GFAP immune-labelling to visualize astrocytes in Control and s-GO treated slices (50 $\mu\text{g}/\text{mL}$). Both
 571 cultures were labelled for GFAP (in green) and nuclei (DAPI; in blue) Scale bar 100 μm . Note that
 572 the GFAP+ cell density did not differ between the two conditions (column plot). In (B),
 573 immunofluorescence images are shown to visualize glial and microglial cells in Control and s-GO
 574 (50 $\mu\text{g}/\text{mL}$) treated slices (anti-Iba1, in red; anti-GFAP in green; DAPI in blue). Scale bar 50 μm .
 575 Note that Iba1+ cell density was significantly (** $P < 0.01$) increased by s-GO (50 $\mu\text{g}/\text{mL}$; right
 576 column plot). (C), Plots summarize the Milliplex assay measures to assess the production of the
 577 following cytokines in organotypic culture supernatant: IL6, IL10, TNF and BAFF and chemokines:
 578 CXCL1, CXCL2, CXCL10 and MCP1 in the presence or absence of s-GO, after 2 weeks *in vitro*.
 579 Column graphs report mean values \pm SEM of 5 independent experiments.

580

581 **Figure 4. Increased cell reactivity in pure microglia cell cultures exposed to s-GO.** In (A),
582 immunofluorescence micrographs visualize microglia by Iba1 labelling (in red) in Control and s-GO
583 treated cultures (10 µg/mL). Scale bar 50 µm. The column graph summarizes microglial density in
584 the two conditions. Note that Iba1+ cell density is significantly ($*** P < 0.001$) higher in cultures
585 treated by s-GO. In (B), high magnification confocal micrographs of Iba1+ cells highlight their
586 morphology in the two conditions. The right column plots summarizes perimeter, Ferret's maximum
587 diameter and transformation index, parameters that describe cellular ramification. All of them are
588 significantly reduced after s-GO exposure ($***P_{\text{perimeter}} < 0.0001$, $**P_{\text{Ferret's diameter}} < 0.001$,
589 $***P_{\text{transformation index}} < 0.0001$; Mann-Whitney test).
590 In (C), box plots show the brdU+/Iba1+ ratio measured in isolated microglial cultures 24 h and 5
591 days after s-GO exposure (10 µg/mL) ($*** P < 0.001$). In (D), western blot analysis of the MVs
592 marker flotillin-1 in each condition. Microvesicles were isolated from glial cultures incubated with s-
593 GO (10 µg/mL) for 6 days and then treated or not with bzATP.

594
595 **Figure 5. s-GO activates microglia phagocytosis in pure neuroglia cultures.** Representative
596 confocal reconstruction of microglial cells in Control or s-GO (10 µg/mL) treated cultures. Scale bar
597 20 µm. In the bottom panel, for both conditions a 60 × zoom (50 × 50 µm field) of a single microglial
598 cell is shown. Scale bar 20 µm. Cultures are immunostained for Iba1 (in grey), and DAPI (in blue), s-
599 GO is visualized by the reflection mode of the confocal system (in yellow). s-GO sheets are visible as
600 aggregates coloured in yellow inside the cell.

601 **6 Conflict of Interest**

602 The authors declare that the research was conducted in the absence of any commercial or financial
603 relationships that could be construed as a potential conflict of interest.

604 **7 Author Contributions**

605 M.M. and R.R. performed all cell biology, electrophysiology, and confocal experiments and analysis;
606 A.F.R. and K.K. contributed to the synthesis and characterization of thin graphene oxide (s-GO);
607 E.B. and C.B. designed and performed the supernatant measures; C.B. and L.B. conceived the study
608 and the experimental design; C.B., R.R. and L.B. wrote the manuscript.

609 **8 Funding**

610 We acknowledged financial support from the European Union's Horizon 2020 research and
611 innovation programme under grant agreement No. 696656 and No. 785219 Graphene Flagship.

612 **9 Acknowledgments**

613 We are especially grateful to Gabriele Baj for the confocal reconstructions of microglial cells
614 generated at the Light Microscopy Imaging Center (LMIC) of the University of Trieste - Life
615 Sciences Department. We are indebt with Dr Neus Lozano for her help in providing the intial s-GO.

616 **10 References**

- 617 Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V., May, L., Guha, A., et al. (2008). Intercellular
618 transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. *Nat.*
619 *Cell Biol.* 10, 619–624. doi:10.1038/ncb1725.
- 620 Aldinucci, A., Turco, A., Biagioli, T., Toma, F. M., Bani, D., Guasti, D., et al. (2013). Carbon
621 Nanotube Scaffolds Instruct Human Dendritic Cells: Modulating Immune Responses by
622 Contacts at the Nanoscale. *Nano Lett.* 13, 6098–6105. doi:10.1021/nl403396e.
- 623 Ali-Boucetta, H., Bitounis, D., Raveendran-Nair, R., Servant, A., Van den Bossche, J., and
624 Kostarelos, K. (2013). Purified Graphene Oxide Dispersions Lack In Vitro Cytotoxicity and In
625 Vivo Pathogenicity. *Adv. Healthc. Mater.* 2, 433–441. doi:10.1002/adhm.201200248.
- 626 Antonucci, F., Turola, E., Riganti, L., Caleo, M., Gabrielli, M., Perrotta, C., et al. (2012).
627 Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid
628 metabolism. *EMBO J.* 31, 1231–40. doi:10.1038/emboj.2011.489.
- 629 Avossa, D., Grandolfo, M., Mazzarol, F., Zatta, M., and Ballerini, L. (2006). Early signs of
630 motoneuron vulnerability in a disease model system: Characterization of transverse slice
631 cultures of spinal cord isolated from embryonic ALS mice. *Neuroscience* 138, 1179–1194.
632 doi:10.1016/j.neuroscience.2005.12.009.
- 633 Avossa, D., Rosato-Siri, M. D., Mazzarol, F., and Ballerini, L. (2003). Spinal circuits formation: a
634 study of developmentally regulated markers in organotypic cultures of embryonic mouse spinal
635 cord. *Neuroscience* 122, 391–405.
- 636 Baldrighi, M., Trusel, M., Tonini, R., and Giordani, S. (2016). Carbon Nanomaterials Interfacing
637 with Neurons: An In vivo Perspective. *Front. Neurosci.* 10, 250. doi:10.3389/fnins.2016.00250.
- 638 Ballerini, L., and Galante, M. (1998). Network bursting by organotypic spinal slice cultures in the
639 presence of bicuculline and/or strychnine is developmentally regulated. *Eur. J. Neurosci.* 10,
640 2871–9.
- 641 Ballerini, L., Galante, M., Grandolfo, M., and Nistri, A. (1999). Generation of rhythmic patterns of
642 activity by ventral interneurons in rat organotypic spinal slice culture. *J. Physiol.* 517 (Pt 2),
643 459–75. doi:10.1111/J.1469-7793.1999.0459T.X.
- 644 Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., et al. (2017).
645 Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and
646 impact on pharmacokinetics. *Nat. Commun.* 8, 777. doi:10.1038/s41467-017-00600-w.
- 647 Bianco, F., Perrotta, C., Novellino, L., Francolini, M., Riganti, L., Menna, E., et al. (2009). Acid
648 sphingomyelinase activity triggers microparticle release from glial cells. *EMBO J.* 28, 1043–54.
649 doi:10.1038/emboj.2009.45.
- 650 Block, M. L., Zecca, L., and Hong, J. S. (2007). Microglia-mediated neurotoxicity: uncovering the
651 molecular mechanisms. *Nat. Rev. Neurosci.* 8, 57–69. doi:10.1038/nrn2038.
- 652 Bramini, M., Sacchetti, S., Armirotti, A., Rocchi, A., Vázquez, E., León Castellanos, V., et al.

- 653 (2016). Graphene Oxide Nanosheets Disrupt Lipid Composition, Ca²⁺ Homeostasis, and
654 Synaptic Transmission in Primary Cortical Neurons. *ACS Nano* 10, 7154–7171.
655 doi:10.1021/acsnano.6b03438.
- 656 Calegari, F., Coco, S., Taverna, E., Bassetti, M., Verderio, C., Corradi, N., et al. (1999). A regulated
657 secretory pathway in cultured hippocampal astrocytes. *J. Biol. Chem.* 274, 22539–47.
- 658 Caldeira, C., Oliveira, A. F., Cunha, C., Vaz, A. R., Falcão, A. S., Fernandes, A., et al. (2014).
659 Microglia change from a reactive to an age-like phenotype with the time in culture. *Front. Cell.*
660 *Neurosci.* 8, 152. doi:10.3389/fncel.2014.00152.
- 661 Carp, J. S. (1992). Physiological properties of primate lumbar motoneurons. *J. Neurophysiol.* 68,
662 1121–32. doi:10.1152/jn.1992.68.4.1121.
- 663 Cherry, J. D., Olschowka, J. A., and O'Banion, M. (2014). Neuroinflammation and M2 microglia: the
664 good, the bad, and the inflamed. *J. Neuroinflammation* 11, 98. doi:10.1186/1742-2094-11-98.
- 665 Chiacchiaretta, M., Bramini, M., Rocchi, A., Armirotti, A., Giordano, E., Vázquez, E., Bandiera, T.,
666 Ferroni, S., Cesca, F., Benfenati, F. (2018). Graphene oxide upregulates the homeostatic
667 functions of primary astrocytes and modulates astrocyte-to-neuron communication. *Nano Lett.*
668 doi: 10.1021/acs.nanolett.8b02487
- 669 Cohen, G. M. (1997). Caspases: the executioners of apoptosis. *Biochem J.* 326, 1-16
- 670 Davalos, D., Grutzendler, J., Yang, G., Kim, J. V, Zuo, Y., Jung, S., et al. (2005). ATP mediates
671 rapid microglial response to local brain injury in vivo. *Nat. Neurosci.* 8, 752–758.
672 doi:10.1038/nn1472.
- 673 del Conde, I., Shrimpton, C. N., Thiagarajan, P., and López, J. A. (2005). Tissue-factor-bearing
674 microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.
675 *Blood* 106, 1604–1611. doi:10.1182/blood-2004-03-1095.
- 676 Djuric, U., Cheung, A. Y. L., Zhang, W., Mok, R. S., Lai, W., Piekna, A., et al. (2015). MECP2e1
677 isoform mutation affects the form and function of neurons derived from Rett syndrome patient
678 iPS cells. *Neurobiol. Dis.* 76, 37–45. doi:10.1016/j.nbd.2015.01.001.
- 679 Fabbro, A., Bosi, S., Ballerini, L., and Prato, M. (2012). Carbon Nanotubes: Artificial Nanomaterials
680 to Engineer Single Neurons and Neuronal Networks. *ACS Chem. Neurosci.* 3, 611–618.
681 doi:10.1021/cn300048q.
- 682 Fabbro, A., Pastore, B., Nistri, A., Ballerini, L. (2007). Activity-independent intracellular Ca²⁺
683 oscillations are spontaneously generated by ventral spinal neurons during development in vitro.
684 *Cell Calcium* 41, 317-329. doi: 10.1016/j.ceca.2006.07.006
- 685 Farina, C., Aloisi, F., and Meinl, E. (2007). Astrocytes are active players in cerebral innate immunity.
686 *Trends Immunol.* 28, 138–145. doi:10.1016/j.it.2007.01.005.
- 687 Fetler, L., and Amigorena, S. (2005). NEUROSCIENCE: Brain Under Surveillance: The Microglia
688 Patrol. *Science (80)*. 309, 392–393. doi:10.1126/science.1114852.

- 689 Fischer, H. P., Marksteiner, J., Ransmayr, G., Saria, A., and Humpel, C. (1998). NGF but not GDNF
690 or neurturin enhance acetylcholine tissue levels in striatal organotypic brain slices. *Int. J. Dev.*
691 *Neurosci.* 16, 391–401.
- 692 Fujita, H., Tanaka, J., Toku, K., Tateishi, N., Suzuki, Y., Matsuda, S., et al. (1996). Effects of GM-
693 CSF and ordinary supplements on the ramification of microglia in culture: a morphometrical
694 study. *Glia* 18, 269–81.
- 695 Furlan, F., Guasti, L., Avossa, D., Becchetti, A., Cilia, E., Ballerini, L., et al. (2005). Interneurons
696 transiently express the ERG K⁺ channels during development of mouse spinal networks in vitro.
697 *Neuroscience* 135, 1179–1192. doi:10.1016/j.neuroscience.2005.06.040.
- 698 Furlan, F., Taccola, G., Grandolfo, M., Guasti, L., Arcangeli, A., Nistri, A., et al. (2007). ERG
699 Conductance Expression Modulates the Excitability of Ventral Horn GABAergic Interneurons
700 That Control Rhythmic Oscillations in the Developing Mouse Spinal Cord. *J. Neurosci.* 27,
701 919–928. doi:10.1523/JNEUROSCI.4035-06.2007.
- 702 Galante, M., Nistri, A., and Ballerini, L. (2000). Opposite changes in synaptic activity of organotypic
703 rat spinal cord cultures after chronic block of AMPA/kainate or glycine and GABAA receptors.
704 *J. Physiol.* 523 Pt 3, 639–51. doi:10.1111/J.1469-7793.2000.T01-1-00639.X.
- 705 Gräfe, C., Weidner, A., Lühe, M. v.d., Bergemann, C., Schacher, F. H., Clement, J. H., et al. (2016).
706 Intentional formation of a protein corona on nanoparticles: Serum concentration affects protein
707 corona mass, surface charge, and nanoparticle–cell interaction. *Int. J. Biochem. Cell Biol.* 75,
708 196–202. doi:10.1016/j.biocel.2015.11.005.
- 709 Hadjidemetriou, M., Al-Ahmady, Z., Mazza, M., Collins, R. F., Dawson, K., and Kostarelos, K.
710 (2015). *In Vivo* Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-
711 Targeted Lipid Bilayer Nanoscale Vesicles. *ACS Nano* 9, 8142–8156.
712 doi:10.1021/acsnano.5b03300.
- 713 Hailer, N. P., Jarhult, J. D., and Nitsch, R. (1996). Resting microglial cells in vitro: analysis of
714 morphology and adhesion molecule expression in organotypic hippocampal slice cultures. *Glia*
715 18, 319–31.
- 716 Hanisch, U.-K. (2002). Microglia as a source and target of cytokines. *Glia* 40, 140–155.
717 doi:10.1002/glia.10161.
- 718 Jasim, D. A., Lozano, N., and Kostarelos, K. (2016). Synthesis of few-layered, high-purity graphene
719 oxide sheets from different graphite sources for biology. *2D Mater.* 3, 014006.
720 doi:10.1088/2053-1583/3/1/014006.
- 721 Jin, X., and Yamashita, T. (2016). Microglia in central nervous system repair after injury. *J.*
722 *Biochem.* 159, 491–496. doi:10.1093/jb/mvw009.
- 723 Jung, I., Pelton, M., Piner, R., Dikin, D. A., Stankovich, S., Watcharotone, S., Hausner, M., Ruoff, R.
724 S. (2007). Simple approach for high-contrast optical imaging and characterization of graphene-
725 based sheets. *Nano Lett.* 7, 3569–3575. doi: 10.1021/nl0714177
- 726 Kabba, J. A., Xu, Y., Christian, H., Ruan, W., Chenai, K., Xiang, Y., et al. (2018). Microglia:

- 727 Housekeeper of the Central Nervous System. *Cell. Mol. Neurobiol.* 38, 53–71.
728 doi:10.1007/s10571-017-0504-2.
- 729 Kettenmann, H., Hanisch, U.-K., Noda, M., and Verkhratsky, A. (2011). Physiology of Microglia.
730 *Physiol. Rev.* 91, 461–553. doi:10.1152/physrev.00011.2010.
- 731 Kettenmann, H., Kirchhoff, F., and Verkhratsky, A. (2013). Microglia: New Roles for the Synaptic
732 Stripper. *Neuron* 77, 10–18. doi:10.1016/j.neuron.2012.12.023.
- 733 Kim, J., Kim, F., Huang, J. (2010). Seeing graphene-based sheets. *Materials Today* 13, 28-38.
734 doi:10.1016/S1369-7021(10)70031-6
- 735 Kostarelos, K., and Novoselov, K. S. (2014). Exploring the Interface of Graphene and Biology.
736 *Science (80-.)*. 344, 261–263. doi:10.1126/science.1246736.
- 737 Kurpius, D., Wilson, N., Fuller, L., Hoffman, A., and Dailey, M. E. (2006). Early activation, motility,
738 and homing of neonatal microglia to injured neurons does not require protein synthesis. *Glia* 54,
739 58–70. doi:10.1002/glia.20355.
- 740 Li, N., Zhang, Q., Gao, S., Song, Q., Huang, R., Wang, L., et al. (2013). Three-dimensional graphene
741 foam as a biocompatible and conductive scaffold for neural stem cells. *Sci. Rep.* 3, 1604.
742 doi:10.1038/srep01604.
- 743 Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., et al.
744 (2017). Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* 541, 481–487.
745 doi:10.1038/nature21029.
- 746 Liu, J., Cui, L., and Losic, D. (2013). Graphene and graphene oxide as new nanocarriers for drug
747 delivery applications. *Acta Biomater.* 9, 9243–9257. doi:10.1016/J.ACTBIO.2013.08.016.
- 748 Mao, H. Y., Laurent, S., Chen, W., Akhavan, O., Imani, M., Ashkarran, A. A., et al. (2013).
749 Graphene: Promises, Facts, Opportunities, and Challenges in Nanomedicine. *Chem. Rev.* 113,
750 3407–3424. doi:10.1021/cr300335p.
- 751 Matcovitch-Natan, O., Winter, D. R., Giladi, A., Vargas Aguilar, S., Spinrad, A., Sarrazin, S., et al.,
752 (2016). Microglia development follows a stepwise program to regulate brain homeostasis.
753 *Science.* 353, aad8670. doi: 10.1126/science.aad8670.
- 754 Medelin, M., Giacco, V., Aldinucci, A., Castronovo, G., Bonechi, E., Sibilla, A., et al. (2018).
755 Bridging pro-inflammatory signals, synaptic transmission and protection in spinal explants in
756 vitro. *Mol. Brain* 11, 3. doi:10.1186/s13041-018-0347-x.
- 757 Medelin, M., Rancic, V., Cellot, G., Laishram, J., Veeraraghavan, P., Rossi, C., et al. (2016). Altered
758 development in GABA co-release shapes glycinergic synaptic currents in cultured spinal slices
759 of the SOD1^{G93A} mouse model of amyotrophic lateral sclerosis. *J. Physiol.* 594, 3827–3840.
760 doi:10.1113/JP272382.
- 761 Mitchell, D. M., Lovel, A. G., and Stenkamp, D. L. (2018). Dynamic changes in microglial and
762 macrophage characteristics during degeneration and regeneration of the zebrafish retina. *J.*
763 *Neuroinflammation* 15, 163. doi:10.1186/s12974-018-1185-6.

- 764 Mukherjee, S. P., Lozano, N., Kucki, M., Del Rio-Castillo, A. E., Newman, L., Vázquez, E., et al.
765 (2016). Detection of Endotoxin Contamination of Graphene Based Materials Using the TNF- α
766 Expression Test and Guidelines for Endotoxin-Free Graphene Oxide Production. *PLoS One* 11,
767 e0166816. doi:10.1371/journal.pone.0166816.
- 768 Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. (2005). Resting Microglial Cells Are Highly
769 Dynamic Surveillants of Brain Parenchyma in Vivo. *Science (80-.)*. 308, 1314–1318.
770 doi:10.1126/science.1110647.
- 771 Nowakowski, R. S., Lewin, S. B., and Miller, M. W. (1989). Bromodeoxyuridine
772 immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic
773 phase for an anatomically defined population. *J. Neurocytol.* 18, 311–318.
774 doi:10.1007/BF01190834.
- 775 Okada, S., Hara, M., Kobayakawa, K., Matsumoto, Y., and Nakashima, Y. (2018). Astrocyte
776 reactivity and astrogliosis after spinal cord injury. *Neurosci. Res.* 126, 39–43.
777 doi:10.1016/j.neures.2017.10.004.
- 778 Olson, J. K. (2010). Immune response by microglia in the spinal cord. *Ann. N. Y. Acad. Sci.* 1198,
779 271–278. doi:10.1111/j.1749-6632.2010.05536.x.
- 780 Paolicelli, R. C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M.,
781 Ferreira, T. A., Guiducci, E., Dumas, L., Ragozzino, D., Gross, C. T. (2011). Synaptic pruning
782 by microglia is necessary for normal brain development. *Science* 333, 1456-1458. doi:
783 10.1126/science.1202529.
- 784 Patskovsky, S., Bergeron, E., Rioux, D., Meunier, M. (2015). Wide-field hyperspectral 3D imaging
785 of functionalized gold nanoparticles targeting cancer cells by reflected light microscopy. *J*
786 *Biophotonics* 8, 401-407. doi: 10.1002/jbio.201400025
- 787 Raastad, M., Storm, J. F., and Andersen, P. (1992). Putative Single Quantum and Single Fibre
788 Excitatory Postsynaptic Currents Show Similar Amplitude Range and Variability in Rat
789 Hippocampal Slices. *Eur. J. Neurosci.* 4, 113–117.
- 790 Rauti, R., Lozano, N., León, V., Scaini, D., Musto, M., Rago, I., et al. (2016). Graphene Oxide
791 Nanosheets Reshape Synaptic Function in Cultured Brain Networks. *ACS Nano* 10.
792 doi:10.1021/acsnano.6b00130.
- 793 Rauti, R., Musto, M., Bosi, S., Prato, M., Ballerini, L. (2018). Properties and behavior of carbon
794 nanomaterials when interfacing neuronal cells: How far have we come? *Carbon* 143, 430-446.
795 doi:10.1016/j.carbon.2018.11.026
- 796 Rodrigues, A. F., Newman, L., Lozano, N., Mukherjee, S. P., Fadeel, B., Bussy, C., Kostarelos, K.
797 (2018). A blueprint for the synthesis and characterisation of thin graphene oxide with controlled
798 lateral dimensions for biomedicine. *2D Mater.* 5, 035020. doi:10.1088/2053-1583/aac05c
- 799 Rosato-Siri, M. D., Zoccolan, D., Furlan, F., Ballerini, L. (2004). Interneurone bursts are
800 spontaneously associated with muscle contractions only during early phases of mouse spinal
801 network development: a study in organotypic cultures. *Eur J Neurosci.* 20, 2697-2710. doi:
802 10.1111/j.1460-9568.2004.03740.x

- 803 Saijo, K., and Glass, C. K. (2011). Microglial cell origin and phenotypes in health and disease. *Nat.*
804 *Rev. Immunol.* 11, 775–787. doi:10.1038/nri3086.
- 805 Sanchez, V. C., Jachak, A., Hurt, R. H., and Kane, A. B. (2012). Biological Interactions of Graphene-
806 Family Nanomaterials: An Interdisciplinary Review. *Chem. Res. Toxicol.* 25, 15–34.
807 doi:10.1021/tx200339h.
- 808 Schermer, C., and Humpel, C. (2002). Granulocyte macrophage-colony stimulating factor activates
809 microglia in rat cortex organotypic brain slices. *Neurosci. Lett.* 328, 180–4.
- 810 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., et al. (2012).
811 Fiji: an open-source platform for biological-image analysis. *Nat. Methods* 9, 676–682.
812 doi:10.1038/nmeth.2019.
- 813 Sibilla, S., Fabbro, A., Grandolfo, M., D'Andrea, P., Nistri, A., Ballerini, L. (2009). The patterns of
814 spontaneous Ca²⁺ signals generated by ventral spinal neurons in vitro show time-dependent
815 refinement. *Eur J Neurosci.* 29, 1543-1559. doi: 10.1111/j.1460-9568.2009.06708.x.
- 816 Song, Q., Jiang, Z., Li, N., Liu, P., Liu, L., Tang, M., Cheng, G. (2014). Anti-inflammatory effects of
817 three-dimensional graphene foams cultured with microglial cells. *Biomaterials* 35, 6930-6940.
818 doi: 10.1016/j.biomaterials.2014.05.002
- 819 Streit, J. (1993). Regular oscillations of synaptic activity in spinal networks in vitro. *J. Neurophysiol.*
820 70, 871–878. doi:10.1152/jn.1993.70.3.871.
- 821 Torres-Platas, S. G., Comeau, S., Rachalski, A., Bo, G. D., Cruceanu, C., Turecki, G., et al. (2014).
822 Morphometric characterization of microglial phenotypes in human cerebral cortex. *J.*
823 *Neuroinflammation* 11, 12. doi:10.1186/1742-2094-11-12.
- 824 Tschertter, A., Heuschkel, M. O., Renaud, P., and Streit, J. (2001). Spatiotemporal characterization of
825 rhythmic activity in rat spinal cord slice cultures. *Eur. J. Neurosci.* 14, 179–90.
- 826 Turola, E., Furlan, R., Bianco, F., Matteoli, M., and Verderio, C. (2012). Microglial microvesicle
827 secretion and intercellular signaling. *Front. Physiol.* 3, 149. doi:10.3389/fphys.2012.00149.
- 828 Ulivieri, C., Savino, M. T., Luccarini, I., Fanigliulo, E., Aldinucci, A., Bonechi, E., Benagiano, M.,
829 Ortensi, B., Pelicci, G., D'Elisio, M. M., Ballerini, C., Baldari, C. T. (2016). The adaptor protein
830 Rai/ShcC promotes astrocyte-dependent inflammation during experimental autoimmune
831 encephalomyelitis. *J Immunol.* 197, 480-490. doi: 10.4049/jimmunol.1502063.
- 832 Usmani, S., Aurand, E. R., Medelin, M., Fabbro, A., Scaini, D., Laishram, J., et al. (2016). 3D
833 meshes of carbon nanotubes guide functional reconnection of segregated spinal explants. *Sci.*
834 *Adv.* 2, e1600087. doi:10.1126/sciadv.1600087.
- 835 Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., and Chan, W. C. W. (2012). Nanoparticle Size and
836 Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake. *J. Am. Chem.*
837 *Soc.* 134, 2139–2147. doi:10.1021/ja2084338.
- 838 Wang, Y., Lee, W. C., Manga, K. K., Ang, P. K., Lu, J., Liu, Y. P., et al. (2012). Fluorinated
839 Graphene for Promoting Neuro-Induction of Stem Cells. *Adv. Mater.* 24, 4285–4290.

- 840 doi:10.1002/adma.201200846.
- 841 Wang, Y., Li, Z., Wang, J., Li, J., and Lin, Y. (2011). Graphene and graphene oxide:
842 biofunctionalization and applications in biotechnology. *Trends Biotechnol.* 29, 205–212.
843 doi:10.1016/j.tibtech.2011.01.008.
- 844 Yang, X., Wang, Y., Huang, X., Ma, Y., Huang, Y., Yang, R., et al. (2011). Multi-functionalized
845 graphene oxide based anticancer drug-carrier with dual-targeting function and pH-sensitivity. *J.*
846 *Mater. Chem.* 21, 3448–3454. doi:10.1039/C0JM02494E.
- 847 Yang, X., Zhang, X., Liu, Z., Ma, Y., Huang, Y., and Chen, Y. (2008). High-Efficiency Loading and
848 Controlled Release of Doxorubicin Hydrochloride on Graphene Oxide. *J. Phys. Chem. C* 112,
849 17554–17558. doi:10.1021/jp806751k.
- 850 Zanier, E. R., Fumagalli, S., Perego, C., Pischitta, F., and De Simoni, M.-G. (2015). Shape
851 descriptors of the “never resting” microglia in three different acute brain injury models in mice.
852 *Intensive Care Med. Exp.* 3, 7. doi:10.1186/s40635-015-0039-0.
- 853
- 854

In review

Figure 1.TIF




Figure 2.TIF







Figure 3.TIF






Figure 4.TIF


A



B



C



D




Figure 5.TIF

